Intranasal Botulinum Toxin A for Gustatory and Vasomotor Rhinitis: A Randomized Controlled Trial Comparing Injection and Spray Delivery
Background: Gustatory and vasomotor rhinitis (non-allergic rhinitis, NAR) are disabling conditions driven by neural dysregulation and glandular hypersecretion. Botulinum toxin A (BoNT-A) has emerged as an off-label treatment, but optimal delivery modalities remain undefined. Methods: We conducted a prospective, randomized, triple-blind, placebo-controlled trial. Ninety adults with gustatory or vasomotor rhinitis were randomized 1:1:1 to receive BoNT-A via submucosal injection (n=30), topical spray (n=30), or placebo control (n=30). The primary outcome was the change in composite Visual Analog Scale (VAS) scores at 12 weeks. Secondary outcomes included individual symptom scores, responder rates, and adverse events. Results: Baseline characteristics were comparable across all groups. At 12 weeks, BoNT-A injection yielded the greatest improvement in composite VAS scores, significantly outperforming both the spray and control groups (p<0.001). The spray group also showed significant improvement over the control (p<0.05), but with a significantly smaller effect size than the injection group (p=0.03). Injection delivery was particularly superior for rhinorrhea-dominant phenotypes. Adverse events were mild and transient. Conclusion: Intranasal BoNT-A is highly effective for NAR, but submucosal injection provides superior efficacy compared to topical spray administration. Both modalities are safe and offer a valuable minimally invasive option for refractory cases.
Authors
- Hany Amin Riad
Publication Details
- Journal
- Figshare
- Published
- 2026-11-21
- DOI
- https://doi.org/10.6084/m9.figshare.35082247
- Primary Topic
- Allergic Rhinitis and Sensitization
- Type
- preprint